Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib plus cetuximab versus chemotherapy in previously treated KRAS G12C-mutated advanced colorectal cancer
2023-506241-30-00Phase 3Completed
- Sponsor
- Mirati Therapeutics
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 31
01
Overview
Phase 3, randomised, open-label trial of adagrasib and cetuximab in colorectal cancer (CRC) (2 arms), sponsored by Mirati Therapeutics. Primary endpoints: Overall survival and Progression-free survival. Started Nov 2021; status: completed.
02
Drugs
adagrasibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-506241-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506241-30-00.